[1] |
BAUMGART D C, LE BERRE C. Newer biologic and small-molecule therapies for inflammatory bowel disease[J]. N Engl J Med, 2021, 385(14):1302-1315. DOI: 10.1056/NEJMra1907607.
|
[2] |
KAPLAN G G. The global burden of IBD:from 2015 to 2025[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(12):720-727. DOI: 10.1038/nrgastro.2015.150.
|
[3] |
PARK J, CHEON J H. Incidence and prevalence of inflammatory bowel disease across Asia[J]. Yonsei Med J, 2021, 62(2):99-108. DOI: 10.3349/ymj.2021.62.2.99.
|
[4] |
NG S C, SHI H Y, HAMIDI N,et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:a systematic review of population-based studies[J]. Lancet, 2017, 390(10114):2769-2778. DOI: 10.1016/S0140-6736(17)32448-0.
|
[5] |
KAPLAN G G, NG S C. Globalisation of inflammatory bowel disease:perspectives from the evolution of inflammatory bowel disease in the UK and China[J]. Lancet Gastroenterol Hepatol, 2016, 1(4):307-316. DOI: 10.1016/S2468-1253(16)30077-2.
|
[6] |
STEVENS G A, ALKEMA L, BLACK R E,et al. Guidelines for accurate and transparent health estimates reporting:the GATHER statement[J]. Lancet, 2016, 388(10062):e19-23. DOI: 10.1016/S0140-6736(16)30388-9.
|
[7] |
|
[8] |
CHEN Y. Perspectives of IBD China:is Crohn's and colitis foundation model a solution to health care issues for the country?[J]. Inflamm Bowel Dis, 2018, 24(5):925-929. DOI: 10.1093/ibd/izy056.
|
[9] |
MAO R, CHIEN NG S, CHEN M H. Network clinical collaboration to improve quality of care of patients with inflammatory bowel disease in China[J]. Inflamm Bowel Dis, 2022, 28(Suppl 2):S1-2. DOI: 10.1093/ibd/izac091.
|
[10] |
|
[11] |
BOROWITZ S M. The epidemiology of inflammatory bowel disease:clues to pathogenesis?[J]. Front Pediatr, 2023, 10:1103713. DOI: 10.3389/fped.2022.1103713.
|
[12] |
MENG Q Y, FANG H, LIU X Y,et al. Consolidating the social health insurance schemes in China:towards an equitable and efficient health system[J]. Lancet, 2015, 386(10002):1484-1492. DOI: 10.1016/S0140-6736(15)00342-6.
|
[13] |
SUN Y H, YUAN S, CHEN X J,et al. The contribution of genetic risk and lifestyle factors in the development of adult-onset inflammatory bowel disease:a prospective cohort study[J]. Am J Gastroenterol, 2023, 118(3):511-522. DOI: 10.14309/ajg.0000000000002180.
|
[14] |
GBD Inflammatory Bowel Disease Collaborators. The global,regional,and national burden of inflammatory bowel disease in 195 countries and territories,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(1):17-30. DOI: 10.1016/S2468-1253(19)30333-4.
|
[15] |
ZHULEKU E, ANTOLIN-FONTES B, BORSI A,et al. Burden of disease among patients with prevalent Crohn's disease:results from a large German sickness fund[J]. Int J Colorectal Dis, 2023, 38(1):74. DOI: 10.1007/s00384-023-04368-y.
|
[16] |
HOU B, WU Y X, HUANG S Y. Participating in health insurance and health improvements for the relatively poor population:a propensity score analysis[J]. Front Public Health, 2022, 10:968009. DOI: 10.3389/fpubh.2022.968009.
|
[17] |
FANG E F, SCHEIBYE-KNUDSEN M, JAHN H J,et al. A research agenda for aging in China in the 21st century[J]. Ageing Res Rev, 2015, 24(Pt B):197-205. DOI: 10.1016/j.arr.2015.08.003.
|
[18] |
WANG R, LI Z Q, LIU S J,et al. Global,regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019:a systematic analysis based on the Global Burden of Disease Study 2019[J]. BMJ Open, 2023, 13(3):e065186. DOI: 10.1136/bmjopen-2022-065186.
|
[19] |
QIU Y, REN W, LIU Y,et al. Disease burden of inflammatory bowel disease in China from 1990 to 2017:findings from the global burden of diseases 2017[J]. EClinicalMedicine, 2020, 27:100544. DOI: 10.1016/j.eclinm.2020.100544.
|
[20] |
SREERAMAREDDY C T, MANOHARAN A. Awareness about and E-cigarette use among adults in 15 low- and middle-income countries,2014-2018 estimates from global adult tobacco surveys[J]. Nicotine Tob Res, 2022, 24(7):1095-1103. DOI: 10.1093/ntr/ntab269.
|